Breakthrough: Novel PRMT5 Inhibitors Discovered Through DNA-Encoded Library Screening

Fast Summary

• Research published in Proceedings of the National Academy of Sciences (Volume 122, Issue 20, May 2025) highlights the recurrent loss of the methylthioadenosine phosphorylase (MTAP) gene in human cancers.
• Using a methylthioadenosine (MTA)-directed DNA-encoded libary screening strategy, researchers identified MTA-cooperative PRMT5 binders.
• This advancement paves the way for developing new therapeutic approaches focused on targeting these binders.

Read More

Indian Opinion Analysis
The identification and understanding of the recurrent loss of MTAP genes in cancer represent a significant breakthrough for global oncology research, including India’s healthcare landscape. Wiht india facing high cancer prevalence rates amid increasing population density and varied genetic profiles,such innovations spotlight potential avenues for targeted therapies that could reduce both mortality rates and treatment costs. The precision-driven approach outlined in this study may align with India’s growing emphasis on personalized medicine initiatives under initiatives like Ayushman Bharat Digital Mission.

While this research is primarily at an experimental stage, its findings reinforce India’s chance to invest more prominently in genomic studies tailored to Indian demographics.Collaborating globally on such advancements can help Indian scientists and clinicians harness cutting-edge therapeutics suited to local needs while contributing actively to international scientific discourse.